Pelotero | $3,000,000 | (Jul 19, 2024)
AEREO | $15,000,000 | (Jul 19, 2024)
Momento | $15,000,000 | (Jul 19, 2024)
Beacon Therapeutics
United States
- Alachua, Florida
- 10/07/2024
- Series B
- $170,000,000
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease.
Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss.
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.
The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.
- Industry Biotechnology Research
- Website https://www.beacontx.com/
- LinkedIn https://www.linkedin.com/company/beacon-therapeutics/
Marathon Fusion | $5,900,000 | (Jul 19, 2024)
Thoughtful AI | $20,000,000 | (Jul 19, 2024)
Allium | $16,500,000 | (Jul 19, 2024)
Planned | $35,000,000 | (Jul 19, 2024)
Truvius | $3,200,000 | (Jul 19, 2024)
EdgeRunner AI | $5,500,000 | (Jul 19, 2024)
OnRamp(US) | $14,200,000 | (Jul 19, 2024)
After.com | $10,000,000 | (Jul 19, 2024)
Fibr | $1,800,000 | (Jul 19, 2024)